PMC

Selected peak subjective-effect ratings as a function of THC (60 mg/day), lofexidine (2.4 mg/day) and the THC (60 mg) and lofexidine (2.4 mg/day) combination during marijuana abstinence (inpatient days 5–6); maximum score = 100 mm. Asterisks indicate a significant difference between medication and placebo (* p < 0.05; ** p < 0.01). Error bars represent ± standard error of the mean (SEM).

Objective and subjective measures of sleep, and daily caloric intake during marijuana abstinence as a function of THC (60 mg/day), lofexidine (2.4 mg/day) and the THC (60 mg) and lofexidine (2.4 mg/day) combination (inpatient days 5–6). Asterisks indicate a significant difference between medication and placebo (* p < 0.05; ** p < 0.01). Error bars represent ± standard error of the mean (SEM).

Selected peak ratings on the Drug-effects Questionnaire and ratings of marijuana craving averaged across the session as a function of THC (60 mg/day), lofexidine (2.4 mg/day) and the THC (60 mg) and lofexidine (2.4 mg/day) combination during marijuana abstinence (inpatient days 5–6). Asterisks indicate a significant difference between medication and placebo (* p < 0.05; ** p < 0.01). Error bars represent ± standard error of the mean (SEM).

Average amount of money spent on marijuana self-administration during the four days following a 3-day period of marijuana abstinence (inpatient days 7–10) as a function of THC (60 mg/day), lofexidine (2.4 mg/day) and the THC (60 mg) and lofexidine (2.4 mg/day) combination. Asterisks indicate a significant difference between medication and placebo (* p < 0.05; ** p < 0.01). Error bars represent ± standard error of the mean (SEM).